Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

BusinessWire_EN 
0 0 04.08.20
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
 

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 11:00 a.m. EDT.

In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of lupus nephritis (Anticipated PDUFA date: January 22, 2021) and evaluating voclosporin ophthalmic solution (VOS) in a Phase 2/3 study for the treatment of dry eye syndrome. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005227/en/

Aurinia Pharmaceuticals Inc. Stock

€4.70
1.950%
There is an upward development for Aurinia Pharmaceuticals Inc. compared to yesterday, with an increase of €0.088 (1.950%).
With 1 Sell predictions and 0 Buy predictions the community sentiment towards the Aurinia Pharmaceuticals Inc. stock is not clear.
On the other hand, the target price of 10 € is above the current price of 4.7 € for Aurinia Pharmaceuticals Inc., so the potential is actually 112.86%.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!